DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Niacin Therapy on Lipoprotein Composition and Function

Not Applicable

Completed

Conditions: Cardiovascular Disease

Interventions: Dietary Supplement: Niacin Extended Release

First Posted Date: 2014-12-23

Last Posted Date: 2025-03-14

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 22

Registration Number: NCT02322203

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide

First Posted Date: 2014-12-23

Last Posted Date: 2020-05-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 273

Registration Number: NCT02322320

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
BMT Group of Georgia (Northside Hospital), Atlanta, Georgia, United States

and more 39 locations

Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

Completed

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2014-12-12

Last Posted Date: 2024-02-09

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 63

Registration Number: NCT02315586

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Genes Involved in Lipid Disorders

Completed

Conditions: Lipid Disorders

First Posted Date: 2014-12-08

Last Posted Date: 2025-05-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 140

Registration Number: NCT02311335

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prospective International Study of Coronary Subtraction Using 320 Detector Row CT (CorSub)

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2014-11-27

Last Posted Date: 2019-12-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 13

Registration Number: NCT02303067

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

Phase 2

Completed

Conditions: Alloimmune Platelet Refractoriness
Thrombocytopenia

Interventions: Drug: Eculizumab

First Posted Date: 2014-11-24

Last Posted Date: 2019-01-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 10

Registration Number: NCT02298933

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

Completed

Conditions: Hypertension

First Posted Date: 2014-11-14

Last Posted Date: 2025-03-19

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1692

Registration Number: NCT02290392

Locations: 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access

Phase 1

Completed

Conditions: Aortic Valve Stenosis

Interventions: Procedure: CA-TAVR
Device: Amplatzer Duct Occluder

First Posted Date: 2014-11-02

Last Posted Date: 2019-02-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 172

Registration Number: NCT02280824

Locations: 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
Advocate Heart Institute, Oakbrook Terrace, Illinois, United States
🇺🇸
Cardiovascular Institute of the South, Houma, Louisiana, United States

and more 12 locations

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Phase 1

Terminated

Conditions: MDS (Myelodysplastic Syndrome)
Chronic Lymphocytic Leukemia
AML (Acute Myelogenous Leukemia)
CML (Chronic Myelogenous Leukemia)
Acute Lymphoblastic Leukemia

Interventions: Biological: MVST
Biological: MVSTr

First Posted Date: 2014-09-04

Last Posted Date: 2019-12-17

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 12

Registration Number: NCT02231853

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: MDS
Acute Myelogenous Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphoblastic Leukemia (ALL)
Chronic Myelogenous Leukemia (CML)

Interventions: Device: CliniMACS CD34 selection system
Biological: ULD IL-2

First Posted Date: 2014-08-27

Last Posted Date: 2018-07-05

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 24

Registration Number: NCT02226861

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy